Gladstone Capital Accepts Resignation of Chief Financial Officer David Gladstone
Gladstone Capital Corp disclosed the resignation of David Gladstone as chief financial officer, effective June 2, 2026. The move triggers mandatory SEC disclosures and requires the business development company to identify a permanent or interim replacement within standard regulatory timeframes.
247wallst.comWASHINGTON, June 2, 2026 — Gladstone Capital Corp reported the departure of David Gladstone from his role as chief financial officer, according to an 8-K filed with the SEC on Tuesday.
The filing, submitted under Items 5.02, 7.01 and 9.01, states that Gladstone resigned from the position. The document does not cite a reason for the departure. David Gladstone also serves as the company's chief executive officer and chairman.
SCOPE Gladstone Capital, a publicly traded business development company with a market focus on debt and equity investments in lower middle market companies, must now operate without its longtime CFO. The company reported total assets of approximately $550 million as of its most recent public filings.
As a regulated investment company under the Investment Company Act of 1940, Gladstone Capital is required to maintain qualified financial leadership to meet SEC reporting, internal controls and portfolio valuation obligations that affect its quarterly 10-Q and annual 10-K filings.
WHAT IT CHANGES Prior to June 2, 2026, David Gladstone held the dual roles of chief executive officer and chief financial officer. Following the effective date of his resignation from the CFO post, the company enters a period in which those functions are separated.
The filing does not specify an immediate successor or whether an interim officer has been named. Under Item 5.02, the company is obligated to disclose any appointment of a principal financial officer in a subsequent 8-K.
WHY IT MATTERS DOWNSTREAM The resignation initiates a regulatory clock for Gladstone Capital to appoint a new principal financial officer and to file any related Form 8-K amendments or exhibits. Failure to maintain a qualified financial reporting officer could delay upcoming periodic filings with the SEC.
The separation of the CEO and CFO roles may also require updates to the company's internal control over financial reporting documentation for its next Sarbanes-Oxley certification. Investors and lenders to the business development company will look for the successor's identity and background, as the CFO signs key valuation assertions and certifies financial statements for a firm that reports quarterly distributions to shareholders.
CONTEXT This marks the first change in Gladstone Capital's principal officer roster disclosed via 8-K in 2026. The company has historically operated with overlapping executive leadership between the CEO and CFO positions, a structure common among smaller business development companies but one that receives heightened scrutiny during leadership transitions.
The filing includes Regulation FD disclosure and exhibits that will be incorporated into the company's ongoing SEC reporting record.
Primary sources: SEC Form 8-K filed June 2, 2026 (Accession No. 0001193125-26-252617).
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Related Stories
thehindu.comU.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect
A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.
prnewswire.comFed Chairman Names Two Outside Advisers During Transition
Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.
insidermonkey.comForte Biosciences Accepts Resignation of Director David Veitch
Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…